ArticleOncoTargets and therapy2026
The EphA3 Antibody Enhances CD47 Antibody-Mediated Phagocytosis by Repolarizing M2-Like Tumor-Associated Macrophages in a Preclinical Model of Recurrent Head and Neck Cancer.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is characterized by a highly immunosuppressive tumor microenvironment (TME), with tumor-associated macrophages (TAMs) playing a central role in resistance to therapy. The immune checkpoint molecule CD47, known for its "don't eat me" signal, and EphA3, a receptor tyrosine kinase, are both upregulated in radiation-resistant HNSCC. However, their cooperative role in regulating TAMs and therapeutic resistance remains poorly understood. Methods: We established a radiation-resistant HNSCC model (MOC2R) using repeated irradiation and confirmed increased expression of CD47 and EphA3 in these cells. The effects of single and dual blockade of CD47 and EphA3 were evaluated through in vitro phagocytosis assays, Western blot, co-immunoprecipitation, and in vivo tumor models. Transcriptomic analysis and immunofluorescence staining were performed to elucidate molecular pathways involved in TAM modulation. We demonstrated in three independent experiments (n = 3) with statistical significance (P < 0.05). Results: CD47 and EphA3 were upregulated in radioresistant HNSCC and recurrent tumors. Dual blockade synergistically enhanced macrophage-mediated phagocytosis (P < 0.01) and significantly reduced clonogenic tumor cell survival compared to single blockade (P < 0.0001). EphA3 inhibition reprogrammed tumor-associated macrophages toward an M1-like phenotype, with increased expression of pro-inflammatory markers and decreased M2-associated markers. In vivo, combination therapy significantly reduced tumor volume and weight and increased M1 macrophage infiltration, while reducing M2 macrophages. Mechanistically, EphA3 regulated macrophage polarization via the β-catenin/FOSL2/ARID5A axis, enhancing the efficacy of CD47 blockade. Conclusion: Our findings demonstrate that EphA3, in cooperation with CD47, promotes an immunosuppressive TME by modulating β-catenin/FOSL2/ARID5A signaling in TAMs. Dual targeting of EphA3 and CD47 represents a promising strategy to reprogram macrophages and enhance anti-tumor immunity in radiation-resistant HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.